Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 May 28;108(10):2039-44.
doi: 10.1038/bjc.2013.199. Epub 2013 May 7.

Expression of steroid receptor coactivator 3 in ovarian epithelial cancer is a poor prognostic factor and a marker for platinum resistance

C Palmieri  1 , O Gojis, B Rudraraju, C Stamp-Vincent, D Wilson, S Langdon, C Gourley, D Faratian
Affiliations

Expression of steroid receptor coactivator 3 in ovarian epithelial cancer is a poor prognostic factor and a marker for platinum resistance

C Palmieri et al. Br J Cancer. .

Abstract

Background: Steroid receptor coactivator 3 (SRC3) is an important coactivator of a number of transcription factors and is associated with a poor outcome in numerous tumours. Steroid receptor coactivator 3 is amplified in 25% of epithelial ovarian cancers (EOCs) and its expression is higher in EOCs compared with non-malignant tissue. No data is currently available with regard to the expression of SRC-3 in EOC and its influence on outcome or the efficacy of treatment.

Methods: Immunohistochemistry was performed for SRC3, oestrogen receptor-α, HER2, PAX2 and PAR6, and protein expression was quantified using automated quantitative immunofluorescence (AQUA) in 471 EOCs treated between 1991 and 2006 with cytoreductive surgery followed by first-line treatment platinum-based therapy, with or without a taxane.

Results: Steroid receptor coactivator 3 expression was significantly associated with advanced stage and was an independent prognostic marker. High expression of SRC3 identified patients who have a significantly poorer survival with single-agent carboplatin chemotherapy, while with carboplatin/paclitaxel treatment such a difference was not seen.

Conclusion: Steroid receptor coactivator 3 is a poor prognostic factor in EOCs and appears to identify a population of patients who would benefit from the addition of taxanes to their chemotherapy regimen, due to intrinsic resistance to platinum therapy.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Ovarian tumour core stained for SRC3: red=SRC3; green=cytokeratin; blue=nuclei; combined image=lower right.
Figure 2
Figure 2
Overall survival based on the expression of SRC3. The colour reproduction of this figure is available on the British Journal of Cancer journal online.
Figure 3
Figure 3
Overall survival based on the expression of SRC3 based on first-line therapy. (A) Single-agent platinum treatment and (B) platinum and taxane doublet.
See this image and copyright information in PMC

References

    1. Ahlgren JD, Ellison NM, Gottlieb RJ, Laluna F, Lokich JJ, Sinclair PR, Ueno W, Wampler GL, Yeung KY, Alt D. Hormonal palliation of chemoresistant ovarian cancer: three consecutive phase II trials of the Mid-Atlantic Oncology Program. J Clin Oncol. 1993;10:1957–1968. - PubMed
    1. Alkner S, Bendahl PO, Grabau D, Lövgren K, Stål O, Rydén L, Fernö M, Swedish and South-East Swedish Breast Cancer Groups AIB1 is a predictive factor for tamoxifen response in premenopausal women. Ann Oncol. 2010;21:238–244. - PubMed
    1. Altman DG, Lausen B, Sauerbrei W, Schumacher M. Dangers of using ‘optimal' cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst. 1994;86:829–835. - PubMed
    1. Bai J, Uehara Y, Montell DJ. Regulation of invasive cell behavior by taiman, a Drosophila protein related to AIB1, a steroid receptor coactivator amplified in breast cancer. Cell. 2000;103:1047–1058. - PubMed
    1. Bowman A, Gabra H, Langdon SP, Lessells A, Stewart M, Young A, Smyth JF. CA125 response is associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer: identification of an endocrine-sensitive subgroup. Clin Cancer Res. 2002;8:2233–2239. - PubMed

Publication types

MeSH terms